

福島県立医科大学 学術機関リポジトリ



Title	多発性硬化症治療学講座(論文・著書・発表等)
Author(s)	
Citation	福島県立医科大学業績集. 4: 369-373
Issue Date	2024-03-21
URL	http://ir.fmu.ac.jp/dspace/handle/123456789/2358
Rights	©2024 福島県立医科大学
DOI	
Text Version	publisher

This document is downloaded at: 2024-06-30T19:29:25Z

多発性硬化症治療学講座

論 文

〔原 著〕

Iwamoto S, Itokazu T, Sasaki A, Kataoka H, Tanaka S, Hirata T, Miwa K, Suenaga T, Takai Y, Misu T, Fujihara K, Yamashita T. RGMa signal in macrophages induces neutrophil-related astrocytopathy in NMO. *Annals of Neurology*. 202204; 91(4):532-547.

Al-Diwani A, Theorell J, Damato V, Bull J, McGlashan N, Green E, Kienzler AK, Harrison R, Hassanali T, Campo L, Browne M, Easton A, Soleymani Majd H, Tenaka K, Iorio R, Dale RC, Harrison P, Geddes J, Qusteded D, Sharp D, Lee ST, Nauen DW, Makuch M, Lennox B, Fowler D, Sheerin F, Waters P, Leite MI. Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis. *Brain*. 202208; 145(8):2742-2754.

Tanaka M, Fujihara K. Difference of anti-viral immunity induced by two mRNA vaccines: Implications in MS patients treated with anti-CD20-depleting therapy. *Clinical and Experimental Neuroimmunology*. 202202; 13(1):5-6.

Menjo K, Ashida S, Murata S, Tanaka E, Fujii C, Tanaka M, Tanaka K, Kanbayashi T, Mizuno T. MOG-antibody-associated disorder with hypothalamic lesions associated with hypersomnia and decrease of orexin in CSF: A case report. *Clinical and Experimental Neuroimmunology*. 202211; 13(4):251-255.

Tanaka K, Tani T, Ogawa K, Kinoshita M, Tanaka M. Trial of cytotoxic T cell induction in mice as an ex vivo model of paraneoplastic neurologic syndrome with anti - Hu antibodies. *Clinical and Experimental Neuroimmunology*. 202211; 13(4):316-322.

Akaishi T, Himori N, Takeshita T, Misu T, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakazawa T, Nakashima I. Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD. *Journal of the Neurological Sciences*. 202206; 437:120269.

Akaishi T, Misu T, Fujihara K, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, aoki M, Nakashima I. Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease. *Journal of Neurology*. 202206; 269(6):3136-3146.

Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, Nakashima I, Levy M, Shang S, Yountz M, Miller L, Armstrong R, Wingerchuk DM; PREVENT Study Group. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. *Multiple Sclerosis*. 202203; 28(3):480-486.

Marignier R, Pittock SJ, Paul F, Kim HJ, Bennett JL, Weinshenker BG, Wingerchuk DM, Green AJ, Fujihara K, Cutter G, Aktas O, Hartung HP, Drappa J, Ratchford JN, She D, Smith M, Rees W, Cimborá D, Katz E, Cree BAC; N-MOMentum study investigators. AQP4-IgG seronegative patient outcomes in the N-MOMentum trial of inebilizumab in neuromyelitis optica spectrum disorder. *Multiple Sclerosis and Related Disorders*. 202201; 57:103356.

Yamamura T, Araki M, Fujihara K, Okuno T, Misu T, Guo YC, Hemingway C, Matsushima J, Sugaya N, Yamashita M, von Büdingen HC, Miyamoto K. Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAKuraSky: a case series. *Multiple Sclerosis and Related Disorders*. 202205; 61:103772.

Tanaka K, Nagaishi A, Matsui M. Autoimmunity to ion channels in neurological diseases—Autoimmunity to aquaporin water channels. *Neurology and Clinical Neuroscience*. 20220628; doi: 10.1111/ncn3.12653.

Wingerchuk DM, Zhang I, Kielhorn A, Royston M, Levy M, Fujihara K, Nakashima I, Tanvir I, Paul F, Pittock SJ. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder. *Neurology and Therapy*. 202205; 11(1):123-135.

Kissani N, Ouadika RJB, Kishk NA, Chaymae O, Ibrahim EAA, Maiga Y, Paul R, Daniel GM, Hamid A, Assogba K, Gaye NM, Hor JY, Tegueu CK, Marignier R, Palace J, Weinshenker BG, Ragab AH, Fujihara K. Neuromyelitis Optica Spectrum Disorders in Africa (A Narrative Review of 622 Cases). *Open Access Library Journal*. 202212; 9(12):e9649.

Okamoto S, Takaki M, Hinotsu K, Kawai H, Sakamoto S, Okahisa Y, Takao S, Tsutsui K, Kanbayashi T, Tanaka K, Yamada N. Impairment of early neuronal maturation in anti-NMDA-receptor encephalitis. *Psychopharmacology*. 202202; 239(2):525-531.

Hinotsu K, Miyaji C, Yada Y, Kawai H, Sakamoto S, Okahisa Y, Tsutsui K, Kanbayashi T, Tanaka K, Takao S, Kishi Y, Takaki M, Yamada N. The validity of atypical psychosis diagnostic criteria to detect anti-NMDA receptor encephalitis with psychiatric symptoms. *Schizophrenia Research*. 202210; 248:292-299.

【総説等】

Bennett JL, Aktas O, Rees WA, Smith MA, Gunsior M, Yan L, She D, Cimborá D, Pittock SJ, Weinshenker BG, Paul F, Marignier R, Wingerchuk D, Cutter G, Green A, Hartung HP, Kim HJ, Fujihara K, Levy M, Katz E, Cree BAC; N-MOMentum study investigators. Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOMentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial. *EBioMedicine*. 202212; 86:104321.

Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaier D, Alvarenga R, Andris C, Asgari N, Barnett Y, Battistella R, Behbehani R, Berger T, Bikbov MM, Biotti D, Biousse V, Boschi A, Brazdil M, Brezhnev A, Calabresi PA, Cordonnier M, Costello F, Cruz FM, Cunha LP, Daoudi S, Deschamps R, de Seze J, Diem R, Etemadifar M, Flores-Rivera J, Fonseca P, Frederiksen J, Frohman E, Frohman T, Tilikete CF, Fujihara K, Gálvez A, Gouider R, Gracia F, Grigoriadis N, Guajardo JM, Habek M, Hawlina M, Martínez-Lapiscina EH, Hooker J, Hor JY, Howlett W, Huang-Link Y, Idrissova Z, Illes Z, Jancic J, Jindahra P, Karussis D, Kerty E, Kim HJ, Lagrèze W, Leocani L, Levin N, Liskova P, Liu Y, Maiga Y, Marignier R, McGuigan C, Meira D, Merle H, Monteiro MLR, Moodley A, Moura F, Muñoz S, Mustafa S, Nakashima I, Noval S, Oehninger C, Ogun O, Omoti A, Pandit L, Paul F, Rebolleda G, Reddel S, Rejdak K, Rejdak R, Rodriguez-Morales AJ, Rougier MB, Sa MJ, Sanchez-Dalmau B, Saylor D, Shatriah I, Siva A, Stiebel-Kalish H, Szatmary G, Ta L, Tenenbaum S, Tran H, Trufanov Y, van Pesch V, Wang AG, Wattjes MP, Willoughby E, Zakaria M, Zvornicanin J, Balcer L, Plant GT. Diagnosis and classification of optic neuritis. *Lancet Neurology*. 202212; 21(12):1120-1134.

Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, Javed A, Mayes D, von Büdingen HC, Klingelschmitt G, Stokmaier D, Bennett JL. Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) from SAKuraSky and SAKuraStar. *Neurology® Neuroimmunology & Neuroinflammation*. 202212; 10(1):e200071.

Joen MY, Seok JM, Fujihara K, Kim BJ. Autoantibodies in central nervous system and neuromuscular autoimmune disorders A narrative review. *Precision and Future Medicine*. 202206; 6(2):105-116.

田中恵子. 抗 NMDA 受容体脳炎. 炎症と免疫. 202206; 30(4):349-353.

田中恵子. 【免疫性神経疾患（第2版）—基礎・臨床の最新知見—】内科疾患や腫瘍に伴う神経免疫疾患 傍腫瘍性神経症候群. *日本臨床*. 202205; 80(増刊 5):513-519.

田中恵子. 傍腫瘍性神経症候群における抗神経抗体と神経症候. *脳神経内科*. 202203; 96(3):262-267.

田中恵子. 【治せる認知症・認知症様状態を見逃さないために】日常臨床で遭遇する治療可能な認知症・認知症様状態 自己免疫性脳炎. *臨床と研究*. 202211; 99(11):27-31.

【その他】

筒井幸, 神林崇, 加藤倫紀, 嵯峨佑史, 三島和夫, 清水徹男, 加藤征夫, 田中恵子. 抗体介在性自己免疫性脳炎と精神医学 抗体介在性自己免疫性脳炎と精神症状. *精神神経学雑誌*. 202204; 124(4 付録):S-448.

書籍等出版物

田中恵子. 第20章 悪性腫瘍に伴うニューロパチー. In: 神田隆. 末梢神経障害: 解剖生理から診断, 治療, リハビリテーションまで. 東京: 医学書院; 202210. p.340-349.

研究発表等（講演・口頭発表等）

〔研究発表〕

田中恵子. アイザックス症候群・スティッフパーソン症候群：疫学調査. 神経免疫班 班会議; 20220113-14; 東京.

田中恵子. 広がり続ける自己免疫性脳炎スペクトラム. 大日本住友製薬セミナーin 秋田; 20220218; 秋田.

田中恵子. 自己免疫性脳炎・脳症の広がりとその背景要因に関する考察. 第118回日本精神神経学会学術総会; 20220616-18; 福岡/Web.

田中恵子. 辺縁系脳炎と自己抗体. 金沢医大神経内科医局セミナー; 20220701; 金沢.

田中恵子. 自己抗体が介在する中枢神経自己免疫疾患—抗体の標的と運動異常症—. 第16回パーキンソン病・運動障害疾患コンgres; 20220721-23; 東京/Web.

田中恵子. 自己免疫性脳炎と認知症. ハッピーフェースセミナー茨城 2022; 20220805; つくば/Web.

田中恵子. 自己免疫性脳炎における発作性症状. 第15回アルツハイマー病とてんかんを考える会; 20220912; 京都.

田中恵子. 自己免疫性脳炎と自己抗体 Up-to-date (イブニングセミナー). 第34回日本神経免疫学会学術集会; 20221020-21; 長崎.

田中恵子. 抗MOG抗体陽性疾患の臨床スペクトラム (モーニングセミナー). 第40回日本神経治療学会学術集会; 20221102-04; 郡山.

田中恵子. 自己免疫性中枢神経炎症性疾患 自己抗体が関連する疾患群 (マラソンレクチャー). 第40回日本神経治療学会学術集会; 20221102-04; 郡山.

田中恵子. 傍腫瘍性神経症候群 Up-to-date (シンポジウム). 第40回日本神経治療学会学術集会; 20221102-04; 郡山.

田中恵子. 見逃されやすい自己免疫性脳炎. 西北五地区精神科医会; 20221130; 青森.

〔招待講演〕

Fujihara K. Case 1: A 44yo man who had aphasia 5 years after brainstem encephalitis, Case 2: A 28yo woman who had weakness and hearing impairment. 3rd Annual Congress of Sri Lanka Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS); 20220129; Colombo, Sri Lanka/Web.

Fujihara K. CNS Demyelination: recent advances and challenges, Therapeutic advances in NMOSD. 3rd

Annual Congress of Sri Lankan Committee for Treatment and Research in Multiple Sclerosis (SLCTRIMS); 20220129; Colombo, Sri Lanka/Web.

Fujihara K. Autoantibody assay methods and their interpretation. Pan-Asian Course for Training in MS And Neuroimmunology (PACTMAN); 20220224; Web.

Fujihara K. SESSION 6 - Special session on NMOSD and other IIDMD of the CNS: NMOSD 2022 - an update. Istanbul MS Days VII; 20220309-11; Cappadocia, Turkey/Web.

Fujihara K. When, how and which patient to assess AQP4-IgG and/or MOG-IgG: practical considerations. 2nd Latin American Virtual Symposium “NMOSD and MOGAD in LATAM: improving patient care”; 20220610; Web.

Fujihara K. Geographic considerations- Asian region. Virtual meeting of International Advisory Committee on Clinical Trials in MS; 20220615-16; Web.

Fujihara K. CTRIMS Session: PACTRIMS and research of MS and related diseases in Asia. Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS). 23rd Annual Meeting; 20220616; Web.

Fujihara K. NMOSD Session: What comes next to double seronegative NMOSD? Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS). 23rd Annual Meeting; 20220617; Web.

Fujihara K. A tumefactive cerebellar lesion followed by medullocervical inflammation 1.5 years later. Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS). ECHO Project; 20220920; Web.

Fujihara K. Selecting first line treatment. BIR MS Medical Education 2022. Evolving Paradigm in Early Management of Multiple Sclerosis; 20220924; Web.

Fujihara K. Pathology of MOGAD. MOG Therapeutic Roundtable; 20220929-30; Cambridge, USA.

Fujihara K. Educational Session 14: Treating NMOSD and MOGAD: How and when to treat AQP4-IgG-positive NMOSD. 38th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 20221028; Amsterdam, Netherland.